Two Renji investigators receive 2022 NSFC General Programme awards

2022 — Good news
Professor Yongming Qiu and Associate Research Professor Yingying Lin awarded 2022 NSFC General Programme grants.
Congratulations on new achievements.
On 8 September, the National Natural Science Foundation of China announced its 2022 review results. Six people from the centre applied, and two received General Programme funding. Renji's Head Trauma Centre and the Shanghai Institute of Head Trauma focus on traumatic, haemorrhagic and tumour-related brain injury and protection. Recent findings include the Qiu team's possible new mechanism for glioma treatment and sequential recombinant HDL and mild hypothermia treatment.
01. Professor Yongming Qiu's funded project

Project: Molecular mechanisms by which radiotherapy-activated AEP cleavage of p53 accelerates repopulation of residual glioblastoma stem-like cells.
Funding category: General Programme.
Expert biography
Yongming Qiu, Professor, Chief Physician and doctoral supervisor, Head Trauma Centre.
As principal investigator, he had led six NSFC projects, five Shanghai Science and Technology Commission projects and other studies. He was selected as a Shanghai Outstanding Discipline Leader and received the Silver Snake Award. His research appeared in JNCI—Journal of the National Cancer Institute, Journal of Experimental & Clinical Cancer Research, Neuro-Oncology and Cancer Letters. He served as guest editor for the Frontiers in Oncology topic “Molecular Biology of Biomarkers in Diagnosis and Treatment of Glioblastoma Multiforme”.
Contact: qiuzhub@126.com.
02. Associate Research Professor Yingying Lin's funded project

Project: Mechanisms by which tumour-microenvironment-triggered AEP cleavage of TMOD3 promotes infiltrative glioblastoma growth.
Funding category: General Programme.
Expert biography
Yingying Lin, Associate Research Professor and master's supervisor, Head Trauma Centre and Shanghai Institute of Head Trauma.
Her group studies proteases and evolution of the tumour microenvironment. It combines biochemical and molecular investigations with clinical samples and models to explain proteases' roles in malignant progression and discover new diagnostic and treatment strategies. As principal investigator, she had led three NSFC projects, three Shanghai Science and Technology Commission projects and other studies. Findings appeared in JNCI, Journal of Experimental & Clinical Cancer Research, Cancer Immunology Research, Cancer Letters, International Journal of Cancer, British Journal of Cancer and International Journal of Biological Sciences. She served as guest editor for the same Frontiers in Oncology topic on biomarkers in glioblastoma diagnosis and treatment.
Contact: yylin@sibs.ac.cn.
Renji's Head Trauma Centre had 11 established clinical physicians and three full-time researchers, all holding doctorates. By the year of this report, nine of these 14 people had obtained 27 NSFC grants, demonstrating the team's research capacity.
Congratulations again to Professor Qiu and Associate Research Professor Lin!
2/0/2/2
喜报
邱永明教授、林盈盈副研究员
获2022年度
国家自然科学基金-面上项目
特此喜报,再创佳绩
9月8日,国家自然科学基金委公布了2022年度评审结果,我中心今年6人申请,其中成功获面上项目资助2人。上海交通大学医学院附属仁济医院颅脑创伤中心及所属上海市颅脑创伤研究所在科研上聚焦于创伤性、出血性、肿瘤性等脑损伤与保护相关研究,近期发表多项研究成果(相关链接:我中心邱永明团队发现脑胶质瘤治疗可能的新机制,我中心研究新成果:重组高密度脂蛋白联合亚低温的序贯治疗)。
01
邱永明教授立项信息

项目名称:放疗激活AEP酶切p53导致残存胶质母细胞瘤干性细胞加速再群体化的分子机制探讨
资助类别:面上项目
-专家介绍-
邱永明,颅脑创伤中心,教授,主任医师,博士生导师
作为第一负责人主持国家自然科学基金项目(6项),上海市科委(5项)等多项课题的研究。入选上海市优秀学科带头人,荣获银蛇奖。相关研究成果在JNCI-Journal of the National Cancer Institute, Journal of Experimental & Clinical Cancer Research, Neuro-Oncology, Cancer Letters等期刊。担任Frontier in Oncology (Molecular Biology of Biomarkers in Diagnosis and Treatment of Glioblastoma Multiforme)客座主编。
联系邮箱:qiuzhub@126.com
02
林盈盈副研究员立项信息

项目名称:肿瘤微环境触发AEP酶切TMOD3促进胶质母细胞瘤浸润性生长的机制研究
资助类别:面上项目
-专家介绍-
林盈盈,颅脑创伤中心,上海市颅脑创伤研究所,副研究员,硕士生导师
课题组围绕蛋白酶与肿瘤微环境演化等问题,从生化分子机制出发,结合临床样本和模型阐释蛋白酶在肿瘤恶性进展中的作用机理,以期发现新的诊疗策略。作为第一负责人主持国家自然科学基金(3项)和上海市科委项目(3项)等多项课题研究。相关研究成果在JNCI-Journal of the National Cancer Institute, Journal of Experimental & Clinical Cancer Research, Cancer Immunology Research, Cancer Letters, International Journal of Cancer, British Journal of Cancer, International Journal of Biological Sciences等期刊。担任Frontier in Oncology (Molecular Biology of Biomarkers in Diagnosis and Treatment of Glioblastoma Multiforme)客座主编。
联系邮箱:yylin@sibs.ac.cn
上海交通大学医学院附属仁济医院颅脑创伤中心,目前共有11名在编临床医生,3名专职科研人员,均具有博士学位。到今年为止,14人中的9人共获得了27项国家自然基金项目,展示了团队强大的科研实力。
再次祝贺邱永明教授和林盈盈副研究员!